Publications by authors named "C Hockham"
High-flux hemodialysis (HD) and high-dose hemodiafiltration (HDF) are established treatments for patients with kidney failure. Since HDF has been associated with improved survival rates compared to HD, we evaluated the cost-effectiveness of HDF compared to HD. Cost-utility analyses were performed from a societal perspective alongside the multinational randomized controlled CONVINCE trial.
View Article and Find Full Text PDFBackground: High-dose haemodiafiltration has been shown, in a randomised clinical trial, to result in a 23% lower risk of mortality for patients with kidney failure when compared with conventional high-flux haemodialysis. Nevertheless, whether treatment effects differ across subgroups, whether a dose-response relationship with convection volume exists, and the effects on cause-specific mortality remain unclear. The aim of this individual patient data meta-analysis was to compare the effects of haemodiafiltration and standard haemodialysis on all-cause and cause-specific mortality.
View Article and Find Full Text PDFArticle Synopsis
- Frequent hemodialysis (more than three times a week) may lower mortality and improve quality of life for kidney failure patients, but the evidence is not clear.
- A systematic review of available studies found only seven eligible trials with a total of 518 participants, indicating limited data on the health effects of frequent hemodialysis.
- The analysis suggested a possibly lower risk of death with frequent hemodialysis, but results were uncertain, and important outcomes like cardiovascular events and patient-reported well-being were largely missing.
Article Synopsis
- * Researchers also assessed health-related quality of life (HRQoL) across various domains, finding that while both groups experienced a decline, the HDF group showed more favorable changes, particularly in cognitive function.
- * Overall, the trial indicated HDF not only benefits survival rates but also helps slow the decline in quality of life aspects for patients, particularly in physical and cognitive functioning.
Background: There are no large studies examining survival in patients receiving haemodialysis in India or considering centre-level effects on survival. We measured survival variation between dialysis centres across India and evaluated the extent to which differences are explained by measured centre characteristics.
Methods: This is a multilevel analysis of patient survival in centres of the NephroPlus dialysis network consisting of 193 centres across India.